DBV Technologies reported positive top‑line results from the pivotal Vitesse Phase 3 trial of its Viaskin peanut patch in children aged 4–7, meeting the trial’s primary endpoint. The trial enrolled more than 650 children and showed a statistically significant treatment effect versus placebo, with responders in the active arm markedly outnumbering placebo. Viaskin delivered desensitization through epicutaneous antigen delivery; 46.6% of treated children met response criteria at 12 months versus 14.8% for placebo. Adverse events were mostly mild‑to‑moderate skin reactions; two children experienced treatment‑related anaphylaxis but continued therapy. DBV plans a BLA submission to the FDA in the first half of next year, seeking to overturn a history of regulatory setbacks that included a 2020 FDA rejection. The outcome represents a commercial inflection point for DBV and a potential new immunotherapy option for pediatric peanut allergy.